Humacyte (NASDAQ:HUMA) Price Target Raised to $12.00

Humacyte (NASDAQ:HUMA) had its target price increased by HC Wainwright from $6.00 to $12.00 in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Humacyte’s FY2028 earnings at $0.71 EPS.

A number of other research firms have also weighed in on HUMA. EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. TD Cowen reaffirmed a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Piper Sandler set a $6.00 price target on Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. BTIG Research reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. Finally, Benchmark reiterated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research note on Thursday, October 10th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Humacyte has an average rating of “Buy” and an average price target of $11.00.

Humacyte Price Performance

Shares of NASDAQ HUMA opened at $5.22 on Tuesday. Humacyte has a 52 week low of $2.08 and a 52 week high of $9.97. The business’s 50 day moving average price is $5.51 and its 200 day moving average price is $6.12. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.61. The firm has a market cap of $623.01 million, a P/E ratio of -4.14 and a beta of 1.47.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, sell-side analysts expect that Humacyte will post -1.09 earnings per share for the current year.

Insider Activity

In related news, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the sale, the director now owns 40,276 shares of the company’s stock, valued at approximately $217,490.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Laura E. Niklason sold 277,090 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total value of $1,792,772.30. Following the transaction, the chief executive officer now owns 4,029,374 shares in the company, valued at $26,070,049.78. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the sale, the director now directly owns 40,276 shares in the company, valued at $217,490.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,084,153 shares of company stock worth $6,869,996 in the last quarter. Corporate insiders own 11.20% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC purchased a new position in shares of Humacyte in the second quarter worth about $28,000. Concurrent Investment Advisors LLC purchased a new position in Humacyte in the 3rd quarter worth approximately $75,000. Principal Financial Group Inc. acquired a new position in shares of Humacyte during the 2nd quarter worth approximately $83,000. Profund Advisors LLC purchased a new stake in shares of Humacyte in the second quarter valued at approximately $97,000. Finally, XTX Topco Ltd acquired a new stake in shares of Humacyte in the second quarter valued at approximately $110,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.